Script Semaglutide

Source index

Semaglutide references

Every number on this site traces to one of these. DOIs and PubMed IDs included.

Back to the researchBack to effects

How to read this index

Every Semaglutide references entry below is a real, published source, listed with its DOI or PubMed identifier so it can be checked. The bracketed numbers in the body text — [1], [2], and so on — map to this list. The record spans the pivotal efficacy trials (STEP, SUSTAIN-6, SELECT, FLOW, SURMOUNT-5), the mechanism work, the emerging alcohol research, and the safety and pharmacovigilance literature. No source is paraphrased into a claim it does not make.

  1. Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. ↗
  2. Marso SP, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. ↗
  3. Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. ↗
  4. Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. ↗
  5. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. ↗
  6. Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. ↗
  7. Aronne LJ, et al. (SURMOUNT-5 Investigators). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
  8. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. ↗
  9. Chuong V, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023. ↗
  10. Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder. Basic Clin Pharmacol Toxicol. 2025. ↗
  11. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide. StatPearls [Internet]. 2024. ↗
  12. Mahapatra MK, et al. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases. Pharm Res. 2022. ↗
  13. McCrimmon RJ, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity. J Endocr Soc. 2021. ↗
  14. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis. J Eur Acad Dermatol Venereol. 2025. ↗
  15. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. ↗
  16. Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022. ↗
  17. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA: A Review. Int J Mol Sci. 2024. ↗
  18. A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data. J Diabetes Investig. 2024. ↗
  19. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. ↗
  20. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021. ↗
  21. Aroda VR, et al. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clin Diabetes. 2023. ↗
  22. Au Yeung SL, et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024. ↗
  23. Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals (Basel). 2025. ↗